Most Read

Under the agreement, Maruho will be responsible for the development and commercialisation of Qbrexza in South Korea, Brunei, Cambodia, Indonesia, Hong Kong, Macau, Vietnam, Malaysia, Philippines, Thailand, Myanmar,

The latest move comes after signing an exclusive licence agreement with HK inno.N in November 2020. The agreement granted sublicensing rights to UITC for developing, marketing, and manufacturing

The latest move is aimed at sharing the government’s objective to make obesity care accessible to patients with high unmet medical need. Through a controlled and limited launch,

The company will utilise proceeds from the round for further developing its technology platform to accelerate its lead programmes to clinical stage. The participants in the financing round

The approval was granted to the company’s Specialty Generics segment, operating as SpecGx. Mallinckrodt started selling the product after securing approval, which happened the day after the expiration

A small molecular compound and a novel type of calcimimetics discovered by Mitsubishi Tanabe Pharma Corporation, Orkedia Tablets suppresses parathyroid hormone (PTH) secretion as it acts on the

The designation will provide certain benefits to Faron including exemption of FDA application fees, tax credits for qualified trials, and on receiving regulatory approval, will get market exclusivity.

These candidates are being developed to offer better protection, extend the duration in preventing illness and transmission, as compared to the current vaccine technologies. As part of the

Ivonescimab is a potential first-in-class investigational PD-1/VEGF bi-specific antibody. It is the company’s other new antibody with a priority review following the marketing approval of cadonilimab. After the